Friday, July 10, 2026

pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)

Taiho Pharma Canada

Taiho Pharma Canada clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA HQ
2017 Founded
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
Founded
2017
Employees
13
Programs
16
Drugs
30
Patents
0
Intelligence · Clinical Programs

Taiho Pharma Canada projects

8 ClinicalTrials.gov programs sponsored by Taiho Pharma Canada.

Taiho Pharma Canada has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ASTX727

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    phase 2 small molecule active

    1 trial
  2. ASTX727-07

    Taiho Pharma Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial
  3. TAS-120

    Taiho Pharma Netherlands B.V.

    Advanced Cholangiocarcinoma

    phase 2 small molecule active

    1 trial
  4. TAS-120-203

    Taiho Pharma Netherlands B.V.

    Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial
  5. TAS-120-206

    Taiho Pharma Netherlands B.V.

    Solid Tumors

    phase 2 small molecule active

    1 trial
  6. TAS-205

    Taiho Pharma Netherlands B.V.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial
  7. TAS-303

    Taiho Pharma Netherlands B.V.

    Stress Urinary Incontinence

    phase 2 small molecule completed

    1 trial
  8. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Taiho Pharma Canada have?

8 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.